Brind.

Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.

1 report, 1 independent Updated Jul 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA Merck Sharp & Dohme European Society for Medical Oncology

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
Merck Sharp & Dohme
company in Madrid, Spain

Nothing else this week.
European Society for Medical Oncology
Professional organisation

Nothing else this week.

Related events

Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.Sep 21

Coverage

Newest first; wire copies grouped

Jul 25GlobeNewswireEvaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (N